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Zusammenfassung
Die Einführung von Imatinib hat die Behandlung für
CML-Patienten in allen Stadien der Erkrankung maßgeb-
lich verbessert. Entsprechend wird Imatinib in internatio-
nalen Therapieempfehlungen als Standardtherapie für
die Erstlinientherapie empfohlen. Trotz der guten Wirk-
samkeit und Verträglichkeit von Imatinib stellt die Resis-
tenzentwicklung eine Herausforderung in der Praxis dar.
Hauptmechanismus für die Entwicklung einer Imatinib-
Resistenz sind Punktmutationen der bcr-abl-Kinasedomä-
ne. Deshalb ist die regelmäßige Kontrolle des hämatolo-
gischen, zytogenetischen und molekularen Ansprechens
unter einer Imatinibtherapie essentiell. Wenn eine zyto-
genetische Remission erreicht wurde, kann die Rester-
krankung durch Bestimmung des bcr-abl-Transkript-Le-
vels durch RT-PCR (reverse transcription polymerase
chain reaction) überwacht werden. Die Identifikation von
bcr-abl-Mutationen vor und während einer Imatinibthera-
pie kann dazu beitragen, die Risikostratifikation und die
sich daraus ableitende Therapieentscheidung zu optimie-
ren. Eine Mutationsanalyse ist angezeigt, wenn ein hä-
matologisches Ansprechen nicht erreicht wird bzw. ver-
loren geht, wenn keine Abnahme der bcr-abl-Transkripte
um 3-log erreicht wird oder ein reproduzierbarer Anstieg
registriert wird. Bei Patienten mit Imatinib-Resistenz
haben Tyrosinkinase-Inhibitoren der 2. Generation eine
vielversprechende Wirksamkeit bei akzeptabler Toxizität
gezeigt. Lediglich die T315I-bcr-abl-Mutation hat sich als
resistent gegenüber allen bisher verfügbaren bcr-abl-Ki-
nase-Inhibitoren erwiesen. Die Suche nach Strategien zur
Verbesserung der Rate der kompletten molekularen Re-
mission wird zukünftig im Fokus der zielgerichteten The-
rapie für CML-Patienten stehen.
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Summary
Imatinib has had marked impact on outcomes in chronic
myelogenous leukemia (CML) patients for all stages of
the disease and is endorsed by international treatment
guidelines as the first line option. Although imatinib is
highly effective and well tolerated, the development of
resistance represents a clinical challenge. Since the most
frequently identified mechanism of acquired imatinib re-
sistance is bcr-abl kinase domain point mutations, peri-
odic hematologic, cytogenetic, and molecular monitor-
ing is critical throughout imatinib therapy. Once cytoge-
netic remission is achieved, residual disease can be
monitored by bcr-abl transcript levels as assayed by re-
verse transcription polymerase chain reaction (RT-PCR).
Detection of bcr-abl mutants prior to and during imatinib
therapy can aid in risk stratification as well as in deter-
mining therapeutic strategies. Thus, mutation screening
is indicated in patients lacking or losing hematologic re-
sponse. Moreover, search for mutations should also be
performed when a 3-log reduction of bcr-abl transcripts
is not achieved or there is a reproducible increase of
transcript levels. In patients harboring mutations which
confer imatinib resistance, novel second line tyrosine ki-
nase inhibitors have demonstrated encouraging efficacy
with low toxicity. Only the T315I bcr-abl mutant has
proved totally resistant to all clinically available bcr-abl
inhibitors. Strategies to further increase the rates of com-
plete molecular remissions represent the next frontier in
the targeted therapy of CML patients.
Dr. Dr. med. Wolfram Dempke
Bristol-Myers Squibb
Abteilung Onkologie
Sapporobogen 6–8, 80637 München, Germany
Tel. +49 89 12142-479, Fax -257
E-mail wolfram.dempke@bms.com
Management of Imatinib-Resistant CML Patients
Rolf Linkea Wolfram Dempkea, b
a Bristol-Myers Squibb, Abteilung Onkologie, München,
bKlinikum Großhadern, Ludwig-Maximilians-Universität München, Germany
© 2007 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/onk
Fax +49 761 4 52 07 14
E-mail Information@Karger.de
www.karger.com
Introduction
The past few decades have witnessed considerable advances in
the understanding of the pathophysiology underlying many
diseases. This knowledge has provided a platform for the de-
velopment of targeted molecular therapies. Defining the mol-
ecular basis of many cancers has shifted the focus of research
towards identifying compounds that specifically inhibit pro-
teins involved in signal transduction within malignant cells.
One of the best examples is the development of treatment
strategies for chronic myeloid leukemia (CML), the first
human malignant disease to be linked to an acquired genetic
abnormality.
CML is a myeloproliferative disorder characterized by the ex-
pansion of a clone of hematopoietic cells that carries the
Philadelphia (Ph) chromosome. The Ph chromosome results
from a reciprocal translocation between the long arms of chro-
mosome 9 and 22: t(9;22)(q34;q11). The molecular conse-
quence of this translocation is the novel fusion gene bcr-abl
which encodes a constitutively active tyrosine kinase (re-
viewed by [1]). The development of imatinib represented a
major success for bcr-abl targeted therapy and a breakthrough
in the management of CML. Before this, treatment options
for CML had been limited, and interferon-α plus cytarabine
was considered standard therapy for patients with CML who
were not planning to undergo allogeneic stem cell transplanta-
tion (SCT). In the phase III IRIS trial, the efficacy of imatinib
was compared with the combination of interferon-α and low-
dose cytarabine in patients with newly chronic phase CML.
The cumulative best rates of complete cytogenetic response
among patients receiving imatinib were 87% by 60 months
(cumulative complete hematologic response after 60 months:
98%). An estimated 7% of patients progressed to accelerated-
phase CML or blast crisis, and the estimated overall survival
of all patients who received imatinib as initial therapy was
89% at 60 months, which is higher than that reported in any
previously published prospective study of the treatment of
CML. Patients who had a complete cytogenetic response or in
whom levels of bcr-abl transcripts had fallen by at least 3-log
below a standardized baseline had a significantly lower risk of
disease progression than did patients without a complete cyto-
genetic response (p < 0.001) [2]. The IRIS study data have es-
tablished imatinib (400 mg/d) as the standard therapy for
CML (fig. 1), and it is currently recommended that imatinib
therapy is continued indefinitely since no evidence exists to
support the belief that patients taking imatinib can safely dis-
continue therapy once they achieve a complete molecular re-
sponse. Most patients who have discontinued imatinib therapy
have rapidly experienced both molecular and cytogenetic re-
lapse, even when some had sustained undetectable levels of
bcr-abl transcripts for long periods [3]. However, in a study
presented by Rousselot et al. [4], the discontinuation of ima-
tinib in CML patients with undetectable residual disease for
more than 2 years was investigated. 50% (6/12) of patients still
had an undetectable level of bcr-abl transcript after a medium
follow-up of 18 months.
A subset of patients with CML will exhibit either primary or
secondary resistance to imatinib. Primary resistance refers to
patients never responding to imatinib, whereas secondary re-
sistance occurs when a patient who had an initial response to
imatinib eventually loses the response. Among patients treat-
ed in chronic phase CML, the rate of resistance has been 
estimated to be 1–5%/year with a decreasing frequency after 
3 years [5] (table 1). Imatinib resistance among patients with
CML is now a clinically significant problem and may limit 
the long-term benefits of the drug, particularly in advanced
disease.
Mechanisms of Imatinib Resistance
Mechanisms of imatinib resistance have been intensively in-
vestigated after first cases of resistance were reported in the
year 2000 [6]. To date, 5 mechanisms of imatinib resistance
have been identified: i) bcr-abl gene mutations; ii) bcr-abl
overexpression/amplification; iii) activation of bcr-abl inde-
pendent kinase pathways; iv) binding to α1-acid glycoprotein
in the plasma; v) increased expression of imatinib efflux
and/or influx transporters.
bcr-abl Gene Mutations
Point mutations in the abl kinase domain are the most fre-
quent mechanisms of acquired imatinib resistance in CML pa-
tients. Imatinib-resistant bcr-abl point mutations have been
found to pre-exist in newly diagnosed CML patients as well as
be acquired to selective pressure of imatinib. Mutations medi-
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Fig. 1. Treatment algorithm for newly diagnosed CML patients in chron-
ic phase. 
*Only for patients with CML in early chronic phase (standard risk).
ating imatinib resistance may occur at any time [7]. These mu-
tations can be classified into 4 groups [8]: i) mutations which
directly affect the imatinib binding site, e.g. T315I, F317L; ii)
mutations within the ATP phosphate binding loop ( = P-loop,
a highly conserved region responsible for phosphate binding),
e.g. E255K, G250E, Q252H, Y253F/H; iii) mutations within
the activation loop (resulting in activated confirmation of abl
which is insensitive to imatinib), e.g. H396R; iv) mutations
within the catalytic domain, e.g. E355G, F359V.
In accordance with the higher sensitivity of detection methods,
the number of identified point mutation has been raised. To
date, more than 73 point mutations have been isolated from
imatinib-resistant CML patients. The biology of some of the
different mutations, their prognosis impact, and their IC50 val-
ues are listed in table 2. Depending on the phase of the dis-
ease, the definition of resistance, and the detection method,
the frequency of bcr-abl mutations in resistant patients was re-
ported to be in the range of 42–90% [9]. Mutations are identi-
fied more frequently in CML patients in accelerated phase or
blast crisis. Detection of bcr-abl mutations in CML patients
treated with imatinib is virtually always accompanied by clini-
cal resistance, and mutations in the P-loop are associated with
a poor prognosis [10]. In most of the cases, only 1 mutation is
identified at the beginning of resistance, while the proportion
of patients with more than 1 kinase mutation is increasing dur-
ing disease progression. Interestingly, it was reported by Shah
et al. [11] that additional mutations identified in association
with alternative tyrosine kinase inhibitors confer in some
cases again sensitivity against imatinib. Not all mutations have
the same clinical impact, and the relationship between ima-
tinib resistance and the occurrence of point mutations in the
bcr-abl domain is not clearly understood. The T315I mutation
and some mutations of the P-loop of bcr-abl are associated
with a greater level of resistance compared to others which
might be overcome by a dose increase of imatinib or which
are functionally irrelevant [12].
bcr-abl Overexpression/Amplification 
Overexpression of the bcr-abl protein due to amplification of
the corresponding gene was first observed in vitro when resis-
tant cell lines were generated by exposure to gradually in-
creasing doses of imatinib. This phenomenon has been report-
ed in relatively small proportion of patients, with an overall
percentage of 18%, but this may be an underestimate if its de-
tection is only based on the cytogenetic findings of Ph chro-
mosome duplication [8]. Overexpression of bcr-abl leads to re-
sistance by increasing the amount of target protein needed to
be inhibited by the therapeutic dose of the drug.
Activation of bcr-abl Independent Kinase Pathways
The src family kinases, Lyn and Hck, are activated in bcr-abl-
expressing cell lines. Lyn is overexpressed and activated in an
imatinib-resistant CML cell line generated by incubation of
the parental line in increasing concentrations of imatinib and
in samples from CML patients who were resistant to imatinib
[13]. Lyn suppression by a src kinase inhibitor resulted in re-
duced proliferation and survival of the imatinib-resistant but
not the sensitive cell line. Molecular analyses have shown that
transcripts from genes with anti-apoptotic or malignant trans-
formation properties and with involvement in signal transduc-
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Table 1. Primary and secondary resistance rates following imatinib treat-
ment (400 mg/d) in CML patients (modified after [5])
CML Primary Secondary 
resistance, % resistance, %
Early chronic phase 4 7
Late chronic phase 4 20
Accelerated phasea 24 60
Blast crisisa 66 93
aImatinib 600 mg/day.
Table 2. Characterization of some bcr-abl mutations conferring imatinib
resistance (modified after [7]. Examples of imatinib-resistant mutations
that destabilize the inactive conformation are those that affect residues
Glu255, Tyr253 and Gly250 in the P-loop of the abl kinase domain. Howe-
ver, many of these mutations are relatively rare, and the most common,
affecting Gly250, Tyr253, Glu255, Thr315, Met351 and Phe359, account
for 60–70% of all mutations [9]
Mutation IC50 Ima- Frequency Mechanism
tinib (nM) in pts.
Wild type 221 NA NA
Leu248Val 1,011 high poorer topological fit
with imatinib
Gly250Ala 313 high unclear
Gly250Glu 2,287 low/medium no imatinib binding
Gln252His 1,080 low/medium destabilization of 
inactive state
Tyr253His > 10,000 high loss of π-π interaction
with imatinib
Tyr253Phe ND high destabilization of 
inactive state
Tyr315Ile > 10,000 high steric hindrance 
(gate keeper)
Phe317Leu 797 high poorer topological fit 
with imatinib
Phe317Val 544 low/medium poorer topological fit 
with imatinib
Met351Thr 593 high unclear
Glu355Gly 601 high no obvious reason for 
resistance
Phe359Val 1,528 high poorer topological fit 
with inhibitor
His396arg ND ND destabilization of 
inactive state
NA = Not applicable; ND = not determined.
tion/transcriptional regulation (e.g. mTOR, p53, GM-CSF) are
overexpressed in CML cells innately resistant to imatinib, sug-
gesting that pathways downstream of bcr-abl and independent
of its kinase activity may be important factors for imatinib re-
sistance [14].
Binding to α1-acid Glycoprotein in Plasma
Drug-binding proteins like α1-acid glycoprotein can capture
imatinib in the plasma, which can result in reduced capability
of imatinib to inhibit bcr-abl kinase activity. The relevance of
this resistance mechanism, however, needs further investiga-
tions [15].
Increased Expression of Imatinib Efflux and/or Influx 
Transporters
A well described mechanism of resistance in cancer therapy is
P-glycoprotein (P-170), a MDR1 (multidrug resistance) gene
product which is able to reduce the intracellular concentration
of a variety of anticancer drugs by an energy (ATP)-depen-
dent efflux. Imatinib and other tyrosine kinase inhibitors are
substrates of P-170. It was shown that the intracellular con-
centration of imatinib is lower in P-170-expressing cells [16].
The clinical relevance of this mechanism for imatinib resis-
tance has to be further evaluated. To date, P-170 overexpres-
sion in imatinib-resistant patients has not yet been reported.
Nevertheless, adding P-170 inhibitors like verapamil to cul-
tures of imatinib-resistant cell lines reduced colony formation
of these cells, suggesting a significant role of P-170 overex-
pression in clinical imatinib resistance [17]. The breast cancer
resistance protein (BCRP)/ABCG2, another drug efflux
pump system, is overexpressed in a number of tumors includ-
ing CML stem cells [18]. The human organic cation trans-
porter 1 (hOCT1) mediates the active transportation of ima-
tinib into cells. Inhibition or low expression of this transport
system may constitute a poorer outcome [19].
It is interesting to note that in terms of gastrointestinal stro-
mal tumors (GISTs) similar mechanisms of imatinib resistance
have been identified. Primary resistance in almost all patients
have tumors bearing either a c-kit mutation in exon 9, a
D842V mutation in PDGFR-α, or a wild-type genotype in
both c-kit and PDGFR-α. The most important event in GIST
patients with secondary imatinib resistance is the occurrence
of c-kit mutations next to the initial mutation (50–70% of all
patients). Secondary mutations predominantly occur in exons
13, 14, 17, or 18 of the c-kit gene, all encoding regions in the
vicinity of the ATP-binding site or the kinase activation loop
of c-kit [20]. Furthermore, c-kit amplifications, increased drug
efflux pumps, and increased levels of α1-acid glycoprotein
have also been identified in imatinib-resistant GIST patients.
For CML patients, methods for predicting and monitoring re-
sponse to treatment have changed considerably in recent
years. Since responses to imatinib may occur at hematologic,
cytogenetic, and molecular levels, the proper follow-up of ima-
tinib-treated patients is based on hematologic, cytogenetic,
and molecular techniques. In the early phases of treatment,
methods which detect residual Ph-positive cells in the blood or
bone marrow are most informative. Once Ph negativity is
achieved, residual leukemia can best be monitored by quanti-
tative reverse transcription polymerase chain reaction (RT-
PCR) assay which measures bcr-abl transcript levels and
reflects the survival of a small number of leukemia cells. In
table 3, the remission definitions are reported.
Recently, definitions of failure and suboptimal response have
also been suggested [12]. Failure implies that the patient
should be switched to other treatments whenever available.
Suboptimal response implies that the patient may still have a
substantial benefit from continuing imatinib treatment, but
the long-term outcome is not likely to be optimal. Some warn-
ings have been proposed to monitor patients very carefully, as
shown in table 4.
Clinical Management of Imatinib-Resistant Patients
Complete cytogenetic response seems to be the most impor-
tant response-relating prognostic factor according to the IRIS
study. Given the high rates of complete cytogenetic response
(CCyR) with imatinib, molecular monitoring of bcr-abl tran-
script levels with RT-PCR technology has become an impor-
tant asset of long-term CML management, and it has emerged
as the method of choice for monitoring residual disease in pa-
tients with CCyR. However, currently, there are various dif-
ferent methods in use for reporting results of RT-PCR data
on individual patients making a reliable comparison of the
data difficult. In an attempt to standardize data of detecting
and measuring bcr-abl transcripts in CML patients of multiple
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Table 3. Response definitions in CML patients following imatinib treat-
ment
Complete hematologic remission
Platelets < 450,000/µl
White blood cell count < 10,000/µl
Differential without immature granulocytes and less than 5% basophils
No palpable spleen
Cytogenetic remission
Complete: Ph+ 0
Partial: Ph+ 1–35%
Minor: Ph+ 36–65%
Minimal: Ph+ 66–95%
None: Ph+ > 95%
Molecular response
Complete: transcript non-quantifiable and non-detectable (standardized
bcr-abl/abl ratio < 0.001%)
Major: standardized bcr-abl/abl ratio < 0.10%
international laboratories, an international scale on which the
standardized ‘baseline’ as established in the IRIS trial is taken
to represent 100%, has been recommended, and a 3-log re-
duction from the standardized baseline (MMR) is fixed at
0.1% [21]. In order to determine the international scale con-
version factor (CF) for each laboratory, RT-PCR values must
be referenced to a set of verified samples of known value (e.g.
plasmids, cell extracts, stabilized RNA). The CF is then de-
rived from the ratio between the value that represents a major
molecular response (MMR) on the international scale and the
laboratory bcr-abl/control gene% value that is equivalent to
the MMR value as established in the IRIS trial. Bcr-abl values
of each laboratory are multiplied by the CF to obtain the cor-
responding bcr-abl levels on the international scale [21].
Molecular responses monitored by RT-PCR have important
clinical implications. At the individual level, RT-PCR studies
can identify the degree of molecular response that predicts
long-term stability and patterns of response that indicate re-
lapse and imatinib resistance. Achieving an MMR (standard-
ized ratio < 0.1%) after 12 months of therapy is associated
with prolonged remission and a significantly better probability
of relapse-free survival [22]. In contrast, increasing levels of
bcr-abl transcripts may be associated with the presence of
point mutations in the kinase domain of the bcr-abl protein.
The detection of bcr-abl point mutations (‘mutation analysis’)
is recommended in any case of treatment failure or subopti-
mal response, including a confirmed (significant) rise of bcr-
abl transcript levels. There is currently no clear evidence that a
chronic phase CML patient defined as high risk (Sokal or
Hasford criteria) is also at high risk for developing point mu-
tations. However, for chronic phase patients who start treat-
ment with imatinib, mutation screening is indicated if there is
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Fig. 2. Schema for the molecular monitoring of CML patients (TKI = ty-
rosine kinase inhibitor; SCT = stem cell transplantation).
Fig. 3. Targets of different tyrosine kinase inhibitors used for treatment of
CML patients.
Table 4. Operational definitions of failure and suboptimal response for
chronic phase CML patients following imatinib therapy (400 g/day)
Imatinib failure
No hematologic remission after 3 months
No complete hematologic remission or no cytogenetic remission after 
6 months
No cytogenetic remission (complete or partial) after 12 months
Loss of hematologic and/or cytogenetic remission (any time)
Suboptimal response
No complete hematologic remission after 3 months
No partial cytogenetic remission after 6 months
No complete cytogenetic remission after 12 months
Less than molecular remission after 18 months
Loss of molecular remission (any time)
Warnings
High risk, del9q+, additional chromosomal abnormalities in Ph+ cells 
(time of diagnosis)
No major molecular remission after 12 months
Any rise in transcript level (bcr-abl/abl ratio), other chromosomal 
abnormalities in Ph+ cells (any time)
Increase of bcr-abl transcripts (1-log) (any time)
inadequate initial response or any sign of loss of response (in-
crease in bcr-abl/abl ratio; fig. 2 and [12]). In advanced phase
CML patients, again mutation analysis is not indicated before
starting imatinib treatment. However, mutation screening is
to be performed in such patients if they fail to respond to ima-
tinib, or if, having responded, they subsequently have rising
numbers of bcr-abl transcripts.
In the case of suboptimal response (definitions see table 4),
the first choice of treatment should be dose escalation of ima-
tinib (600–800 mg/day), provided that the patient tolerated the
initial dose of 400 mg and mutation analyses revealed no bcr-
abl mutation with a high level of imatinib resistance. In pa-
tients who failed imatinib therapy (400 mg/day) (definitions
see table 4), dose escalation (800 mg/day) should only be
taken into account if resistance to imatinib was not associated
with a mutation conferring imatinib resistance. If in both cases
mutations which are not sensitive to imatinib are detected or
the patients are not eligible for imatinib dose escalation, ima-
tinib therapy has to be discontinued, and patients should be
switched to a second line tyrosine kinase inhibitor (e.g. dasa-
tinib (Sprycel®, Bristol-Myers Squibb, Munich, Germany;
FDA and EMEA approved), or other experimental drugs).
Alternatively, allogeneic SCT could be offered to patients 
if a suitable donor is available. Resistance to imatinib
(400–600mg/day) is a well-recognized problem for CML pa-
tients, and escalating the imatinib dose to 800 mg/day can
overcome some of these cases, but the resulting responses are
short in duration and tolerability of high-dose imatinib contin-
ues to be an issue. In a recently published phase II study [23],
patients with imatinib-resistant chronic phase CML were ran-
domized 2:1 to 140 mg dasatinib ( n = 101) or 800 mg imatinib
(n = 49). With a medium follow-up of 15 months, complete
hematologic responses were observed in 93 and 82% of pa-
tients receiving dasatinib and high-dose imatinib (p = 0.034),
respectively. Furthermore, dasatinib resulted in higher major
cytogenetic response rates (52%) than high-dose imatinib
(33%, p = 0.023) including complete cytogenetic responses (40
vs. 10%, p = 0.004), suggesting that dasatinib appears to be
more active than high-dose imatinib in patients who experi-
ence imatinib failure. In patients presenting with warning fea-
tures (definitions see table 4), standard treatment is still ima-
tinib (400 mg/day), but any warning should alert to the possi-
bility that the patient might become eligible for imatinib dose
escalation (600–800 mg/day), allogeneic SCT, or for second
line tyrosine kinase inhibitors (or other investigational drugs).
By minimizing susceptibility to drug-resistant kinase domain
point mutations in preclinical studies, dasatinib, nilotinib
(Tasigna®, Novartis, Basel, Switzerland) and other compounds
represent important advances in CML targeted therapy (re-
viewed by [24]; fig. 3). The early successes of these compounds
suggest that the majority of patients with imatinib-resistant
chronic phase disease will achieve objective responses, but the
durability of responses with theses agents remains to be de-
fined. Clearly, the T315I mutation (‘gatekeeper mutation’)
represents an important gap in the coverage of dasatinib and
nilotinib, and it is possible that the majority of acquired resis-
tance to these compounds will be mediated by selective out-
growth of cells harboring this mutation. To date, the only es-
tablished therapeutic option for patients with the T315I muta-
tion is SCT [25]. If SCT is not applicable, hydroxyurea, homo-
harringtonine, or experimental drugs (e.g. MK-0457) may be
therapeutic alternatives. Although a couple of new com-
pounds have shown activity against T315I bcr-abl in preclini-
cal systems (table 5), recent work in clinical studies has shown
that the Aurora kinase inhibitor MK-0457 (VX-680) can in-
duce objective clinical responses in patients with T315I phe-
notype refractory CML [26]. In addition, PHA-739358 (Ner-
viano Medical Science, Milano, Italy), an orally bio-available
inhibitor of Aurora kinases A, B, and C, has shown potent
anti-proliferative activity in CML cell lines harboring the
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Drug Target molecule T315I Development status
mutation 
activity
Imatinib (Glivec®) bcr/abl, c-kit, PDGF-R no approved (1st line)
Dasatinib (Sprycel®) bcr/abl, c-kit, PDGF-R, src no approved (2nd line)
Nilotinib (Tasigna®) bcr/abl, c-kit, PDGF-R no approval expected in 2007
Bosutinib (SKI-606) bcr/abl, src no phase II
INNO-406 (NS-187) bcr/abl, Lyn no phase I
MK-0457 (VX-680) Aurora A, B, C; bcr/abl, Flt-3 yes phase I/II
PHA-739358 Aurora A, B, C yes phase II
AS 703569 Aurora A, B, C yes phase I
IPI-504 (17-AAG) HSP-90 yes phase I
XL 228 bcr/abl, src, IGF-1-R yes phase I planned
ON012380 bcr/abl, PDGF-R, src, (c-kit) yes phase I planned
SGX-70430 bcr/abl yes preclinical
BIRB-796 bcr/abl, p38 MAP-Kinase yes preclinical
AP23464 bcr/abl, src, c-kit yes preclinical
Table 5. Small molecules for treatment of
CML patients under preclinical and clinical
development (examples)
T315I mutation [7]. Following successful phase I clinical trials,
this compound is currently being studied in a phase II trial in
CML patients who have relapsed after imatinib therapy.
While these results are encouraging, it mains to be determined
whether Aurora kinase inhibitors will be tolerated in patients
or have their own distinct set of resistance mutations, and
highlights the need for clinical-grade inhibitors against the
T315I mutation. Therefore, strategies to override resistance
mediated by the T315I mutation represent the next major
frontier in the targeted treatment of CML and may help to
improve survival in accelerated and blast phase patients.
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